🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. VX-407

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    4 trials

  2. VX-407 tablet

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    1 trial

  3. Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer of Biliary Duct

    phase 2 small molecule active

    1 trial

  4. Volixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule terminated

    1 trial

  5. Vosoritide Injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Noonan Syndrome

    phase 2 small molecule active

    1 trial

  6. Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP), Lyophilized powder for reconstitution, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Idiopathic Short Stature (ISS)

    phase 2 small molecule active

    1 trial

  7. Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP)

    BioMarin Pharmaceutical Australia Pty Ltd

    Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome

    phase 2 small molecule active

    1 trial

  8. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial

  9. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mature B-cell Malignancies

    phase 2 small molecule completed

    1 trial

  10. Zelboraf 240 mg film-coated tablets

    Ningbo Cancer Hospital

    Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment

    phase 2 small molecule active

    1 trial

  11. Ziftomenib

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial

  12. Zilovertamab vedotin

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  13. activated recombinant human factor VII

    Novo Nordisk A/S

    Acquired Bleeding Disorder

    phase 2 small molecule completed

    2 trials

  14. alisertib

    Takeda

    Malignant Rhabdoid Tumor

    phase 2 small molecule active

    1 trial

  15. atumelnant

    Crinetics Pharmaceuticals Europe GmbH

    Cushing Syndrome

    phase 2 small molecule active

    1 trial

  16. atumelnant (CRN04894)

    Crinetics Pharmaceuticals Europe GmbH

    Congenital Adrenal Hyperplasia

    phase 2 small molecule active

    2 trials

  17. buprenorphine taper followed by naltrexone maintenance

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Opioid Dependence

    phase 2 small molecule completed

    1 trial

  18. delolimogene mupadenorepvec

    Chongqing Precision Biotech Co., Ltd

    Malignant Melanoma

    phase 2 gene therapy completed

    1 trial

  19. everolimus

    United Therapeutics Europe Ltd

    Malignant Peripheral Nerve Sheath Tumors

    phase 2 small molecule completed

    1 trial

  20. ganetespib

    United Therapeutics Europe Ltd

    Malignant Peripheral Nerve Sheath Tumors (MPNST)

    phase 2 small molecule completed

    1 trial

  21. iCasp9M28z T cell infusions

    United Therapeutics Europe Ltd

    Malignant Pleural Disease

    phase 2 gene therapy active

    1 trial

  22. implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).

    Lxo Ireland Designated Activity Company

    Cleft Lip and Palate

    phase 2 other active

    1 trial

  23. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  24. low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources